Are Drospirenone and Estradiol the New Treatment for Post-Menopausal Women?

Are Drospirenone and Estradiol the New Treatment for Post-Menopausal Women?

Drospirenone is a key ingredient alongside Estradiol in the birth control pill Angeliq. The patent for Angeliq expires on August 11, 2017, making way for the development of generic options of this versatile hormone regulating medication. Developed as a birth control medication, used to prevent pregnancy, Angeliq works by preventing ovulation and causing changes in the cervical mucus and uterine lining making it harder for pregnancy to occur. In addition to birth control, Drospirenone CAS# 67392-87-4 and Estradiol CAS# 50-28-2, and Estradiol Base Benzoate & derivatives , is now being considered as a hormone replacement therapy in post-menopausal women.

Are Drospirenone and Estradiol the New Treatment for Post-Menopausal Women

In a study completed at Peking Union Medical College Hospital in Beijing, China, two milligrams of Drospirenone was combined with one milligram of Estradiol as hormone replacement therapy in postmenopausal Chinese women. This multicenter, randomized and controlled study involved women experiencing frequent and severe menopausal vasomotor symptoms. The women in the study were between the ages of 45 and 65 years old. Participants were  randomized to receive Drospirenone and Estradiol or a placebo once daily for a total of four 28 day cycles.  A total of 183 women were administered the hormone treatment and 61 women received a placebo. Positive results were revealed from the women who were dosed with Drospirenone and Estradiol, with a little over 80 percent of women reporting a decrease in hot flashes per week, as compared to a little over 50 percent of women that took the placebo who saw a decrease in these episodes. Additionally,  participants who were treated with Drospirenone and Estradiol experienced less sweating episodes and reported a decrease in vaginal dryness.

Side effects of Drospirenone and Estradiol are mild, and may include appetite and weight changes, bloating, decreased libido, increased hair growth, slight nausea, stomach cramps and a tired feeling. The aforementioned study of post-menopausal Chinese women indicated that treatment with Drospirenone and Estradiol was effective, safe and tolerable. Could this be the future of hormone replacement therapy for women who are post-menopausal?

LGM Pharma provides both Drospirenone and Estradiol for research and development purposes, and offers clients complete support throughout the R&D process.

Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

  • Share:

LGM Pharma Acquires CDMO

On July 27, 2020, LGM Pharma announced its acquisition of the formulation development and drug product contract manufacturing business of Nexgen Pharma, Inc. As a result, you will notice our new logo and visuals throughout the website. We’re working on updates to reflect the exciting, expanded CDMO capabilities and services we now can offer you.

This website uses cookies. By using our site, you agree to our terms of service